Undisclosed ovarian cancer vaccine / Anixa Biosci, Cleveland Clinic, National Cancer Institute - LARVOL DELTA

Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology (PRNewswire) - "Anixa Biosciences...announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,357,593 on July 15, 2025 covering key aspects of its ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting anti-Müllerian hormone receptor, type II (AMHR2), a promising target for ovarian cancer prevention and treatment....The patent includes methods of administering an immunogenic composition comprising a nucleic acid encoding the AMHR2 polypeptide, specifically the extracellular domain of human AMHR2, to elicit an AMHR2-specific immune response. This patent was issued to Cleveland Clinic and Anixa exclusively holds the world-wide rights to the patent."

Patent • Ovarian Cancer

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine (PRNewswire) - "Anixa Biosciences, Inc...today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent application covering its ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting Anti-Mullerian Hormone Receptor, Type II (AMHR2), a promising target for ovarian cancer prevention and treatment....Anixa's ovarian cancer vaccine, being developed in collaboration with Cleveland Clinic and the National Cancer Institute, represents a novel approach to preventing and treating ovarian cancer, particularly among high-risk populations such as those carrying BRCA mutations or with a family history of the disease."

Patent • Ovarian Cancer

Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines (PRNewswire) - "Anixa Biosciences...announced that it has entered into a joint development agreement with Cleveland Clinic to develop novel vaccines for various cancer types. Cleveland Clinic is currently conducting a Phase 1 clinical trial targeting triple negative breast cancer (TNBC)...and an ovarian cancer vaccine is in pre-clinical development in collaboration with the National Cancer Institute. The vaccines focus on a novel scientific mechanism never used before in a cancer vaccine. By developing vaccines that immunize against 'retired' proteins found to be expressed in specific forms of cancer, the researchers are investigating if certain cancer cells can be destroyed as they arise, and ultimately prevent tumors from forming....Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company."

Licensing / partnership • Ovarian Cancer • Triple Negative Breast Cancer

Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024 (PRNewswire) - "Anixa Biosciences, Inc....announced its participation in the Sidoti Micro-Cap Virtual Conference, taking place May 8-9, 2024....Dr. Kumar will discuss Anixa's preventative breast cancer vaccine, currently in Phase 1 clinical trials, that is showing strong positive data. Additional data releases expected in the coming months, and a Phase 2 trial is expected to commence in early 2025. Anixa's CAR-T cell therapy treatment for ovarian cancer is also in a Phase 1 trial and showing positive data."

New P2 trial • P1 data • Breast Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology (PRNewswire) - "Anixa Biosciences, Inc...today announced that its partner, Cleveland Clinic, has received an 'Intention to Grant' notice from the European Patent Office ('EPO') for the patent application titled 'Ovarian Cancer Vaccines.'....Anixa's ovarian cancer vaccine targets the extracellular domain of anti-Müllerian hormone receptor 2 (AMHR2-ED), which is expressed in the ovaries but disappears as a woman reaches and advances through menopause."

Patent • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology (PRNewswire) - "Anixa Biosciences, Inc...today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent Number 11,786,489, which broadens protection of Anixa's novel ovarian cancer vaccine technology....Anixa's ovarian cancer vaccine targets the extracellular domain of anti-Müllerian hormone receptor 2 (AMHR2-ED), which is expressed in the ovaries but disappears as a woman reaches and advances through menopause."

Patent • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology (PRNewswire) - "Anixa Biosciences...announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa's novel ovarian cancer vaccine technology, which has been exclusively licensed from, and is being developed in partnership with, Cleveland Clinic. The patent is titled 'Ovarian Cancer Vaccines,' and covers nucleic acid-based delivery of the vaccine....This ovarian cancer vaccine targets the extracellular domain of anti-Müllerian hormone receptor 2 (AMHR2-ED), which is expressed in the ovaries but disappears as a woman reaches and advances through menopause."

Patent • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

Formulation of an ovarian cancer vaccine with the squalene-based AddaVax adjuvant inhibits the growth of murine epithelial ovarian carcinomas. (PubMed, Clin Exp Vaccine Res) - "These results were compared favorably with results obtained using CFA as an adjuvant in the AMHR2-ED vaccine. Our data indicate that the AMHR2-ED vaccine formulated with AddaVax may be used in human clinical trials and thereby serve as a novel and effective way to control human EOC."

Journal • Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer • Pain • Solid Tumor • AMHR2